First approved inhaled insulin therapy for diabetes mellitus

Rucha Jani, Curtis L Triplitt, Charles Reasner, Ralph A Defronzo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The long-term benefits of tight glycemic control in preventing microvascular and macrovascular complications are well established in both Type 1 diabetes mellitus (Type 1 DM) and Type 2 diabetes mellitus (Type 2 DM). Nonetheless, achievement of recommended haemoglobin A1c (HbA1c) goals (≤ 6.5 - 7.0%) has remained elusive, especially in patients with diabetes who require insulin therapy. Delayed/suboptimal titration of insulin is partly related to poor acceptance of multiple injection regimen by both physicians and patients. EXUBERA® (human insulin [rDNA origin]; Pfizer), the first approved inhaled insulin for the treatment of diabetic patients, has been shown to be safe and as effective as regular/rapidly acting insulin in improving glycemic control. In addition to controlling postprandial glucose excursions, EXUBERA exerts a major action to reduce fasting plasma glucose (FPG) concentration. Thus, it has the potential to be used as a monotherapy in Type 2 DM, as well as in combination with an insulin sensitizer in Type 2 DM or in combination with long-acting insulin in both Type 2 DM and Type 1 DM.

Original languageEnglish (US)
Pages (from-to)63-76
Number of pages14
JournalExpert Opinion on Drug Delivery
Volume4
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Diabetes Mellitus
Insulin
Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus
Therapeutics
Long-Acting Insulin
Glucose
Ribosomal DNA
Fasting
Hemoglobins
Physicians
Injections

Keywords

  • Diabetes mellitus
  • EXUBERA
  • Glycemic control
  • Inhaled insulin

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

First approved inhaled insulin therapy for diabetes mellitus. / Jani, Rucha; Triplitt, Curtis L; Reasner, Charles; Defronzo, Ralph A.

In: Expert Opinion on Drug Delivery, Vol. 4, No. 1, 01.2007, p. 63-76.

Research output: Contribution to journalArticle

Jani, Rucha ; Triplitt, Curtis L ; Reasner, Charles ; Defronzo, Ralph A. / First approved inhaled insulin therapy for diabetes mellitus. In: Expert Opinion on Drug Delivery. 2007 ; Vol. 4, No. 1. pp. 63-76.
@article{a8618e68febf44d4ae25dfdcb882581d,
title = "First approved inhaled insulin therapy for diabetes mellitus",
abstract = "The long-term benefits of tight glycemic control in preventing microvascular and macrovascular complications are well established in both Type 1 diabetes mellitus (Type 1 DM) and Type 2 diabetes mellitus (Type 2 DM). Nonetheless, achievement of recommended haemoglobin A1c (HbA1c) goals (≤ 6.5 - 7.0{\%}) has remained elusive, especially in patients with diabetes who require insulin therapy. Delayed/suboptimal titration of insulin is partly related to poor acceptance of multiple injection regimen by both physicians and patients. EXUBERA{\circledR} (human insulin [rDNA origin]; Pfizer), the first approved inhaled insulin for the treatment of diabetic patients, has been shown to be safe and as effective as regular/rapidly acting insulin in improving glycemic control. In addition to controlling postprandial glucose excursions, EXUBERA exerts a major action to reduce fasting plasma glucose (FPG) concentration. Thus, it has the potential to be used as a monotherapy in Type 2 DM, as well as in combination with an insulin sensitizer in Type 2 DM or in combination with long-acting insulin in both Type 2 DM and Type 1 DM.",
keywords = "Diabetes mellitus, EXUBERA, Glycemic control, Inhaled insulin",
author = "Rucha Jani and Triplitt, {Curtis L} and Charles Reasner and Defronzo, {Ralph A}",
year = "2007",
month = "1",
doi = "10.1517/17425247.4.1.63",
language = "English (US)",
volume = "4",
pages = "63--76",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - First approved inhaled insulin therapy for diabetes mellitus

AU - Jani, Rucha

AU - Triplitt, Curtis L

AU - Reasner, Charles

AU - Defronzo, Ralph A

PY - 2007/1

Y1 - 2007/1

N2 - The long-term benefits of tight glycemic control in preventing microvascular and macrovascular complications are well established in both Type 1 diabetes mellitus (Type 1 DM) and Type 2 diabetes mellitus (Type 2 DM). Nonetheless, achievement of recommended haemoglobin A1c (HbA1c) goals (≤ 6.5 - 7.0%) has remained elusive, especially in patients with diabetes who require insulin therapy. Delayed/suboptimal titration of insulin is partly related to poor acceptance of multiple injection regimen by both physicians and patients. EXUBERA® (human insulin [rDNA origin]; Pfizer), the first approved inhaled insulin for the treatment of diabetic patients, has been shown to be safe and as effective as regular/rapidly acting insulin in improving glycemic control. In addition to controlling postprandial glucose excursions, EXUBERA exerts a major action to reduce fasting plasma glucose (FPG) concentration. Thus, it has the potential to be used as a monotherapy in Type 2 DM, as well as in combination with an insulin sensitizer in Type 2 DM or in combination with long-acting insulin in both Type 2 DM and Type 1 DM.

AB - The long-term benefits of tight glycemic control in preventing microvascular and macrovascular complications are well established in both Type 1 diabetes mellitus (Type 1 DM) and Type 2 diabetes mellitus (Type 2 DM). Nonetheless, achievement of recommended haemoglobin A1c (HbA1c) goals (≤ 6.5 - 7.0%) has remained elusive, especially in patients with diabetes who require insulin therapy. Delayed/suboptimal titration of insulin is partly related to poor acceptance of multiple injection regimen by both physicians and patients. EXUBERA® (human insulin [rDNA origin]; Pfizer), the first approved inhaled insulin for the treatment of diabetic patients, has been shown to be safe and as effective as regular/rapidly acting insulin in improving glycemic control. In addition to controlling postprandial glucose excursions, EXUBERA exerts a major action to reduce fasting plasma glucose (FPG) concentration. Thus, it has the potential to be used as a monotherapy in Type 2 DM, as well as in combination with an insulin sensitizer in Type 2 DM or in combination with long-acting insulin in both Type 2 DM and Type 1 DM.

KW - Diabetes mellitus

KW - EXUBERA

KW - Glycemic control

KW - Inhaled insulin

UR - http://www.scopus.com/inward/record.url?scp=33846329408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846329408&partnerID=8YFLogxK

U2 - 10.1517/17425247.4.1.63

DO - 10.1517/17425247.4.1.63

M3 - Article

VL - 4

SP - 63

EP - 76

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 1

ER -